$FCBM

Paul Charles Albert III purchased $88K of FCBM (indirect holdings)

Paul Charles Albert III purchased 7,000 indirectly-held shares of First Carolina Financial Services, Inc. (FCBM) at $12.50 on 2026-06-18.

Original reporting
SEC EDGAR · Paul Charles Albert III
Published Jun 22, 2026, 11:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 22, 2026, 11:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$FCBM
Bullish
low confidence
Mentioned
$FCBM
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$FCBMBullishLow
01

Why it matters

The newest fact is the director’s open-market purchase details (7,000 shares at $12.50/share) disclosed on 2026-06-22.

02

Market read

Traders may note mild positive sentiment from insider buying, but there is no fundamental catalyst beyond the transaction itself.

03

What to watch

No 10b5-1 plan was used per the filing, but the article provides no context on prior trading patterns, motivations, or whether other insiders acted.

Relevance 4/10Novelty 5/10Timing: Filed 2026-06-22 for a 2026-06-18 purchase

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for First Carolina Financial Services, Inc. (FCBM).

Company-level read

Ticker impact

$FCBMBullishLow confidence
Context

FCBM disclosed a Form 4 showing director Paul Charles Albert III bought 7,000 shares at $12.50/share on 2026-06-18 (indirect holdings).

Expected impact

Likely limited immediate price impact; any effect would be sentiment-driven and short-lived.

Evidence & confidence

The filing is a routine insider transaction with modest dollar value (~$87.5k) and no accompanying corporate action, guidance, or operational change.

Market effects

No sector read-through; this is company-specific insider buying with no new business or regulatory development.

None indicated.

None indicated.

Counterpoint

Indirect holdings and a director’s small purchase may reflect diversification or routine estate/plan mechanics rather than a strong forward view.

Key entities

  • First Carolina Financial Services, Inc.

    Subject of the Form 4 insider transaction disclosure (FCBM).

  • Paul Charles Albert III

    Director who reported an open-market purchase of 7,000 shares on 2026-06-18 (indirect holdings).

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$FCBMMed

First Carolina Financial Services Reports Net Income of $7.9 Million, or $0.26 Per Diluted Share, for the Third Quarter of 2026

First Carolina Financial Services, Inc. (FCBM) filed an SEC Form 8-K — Results of Operations and Financial Condition. FOR IMMEDIATE RELEASE: First Carolina Financial Services Reports Net Income of $7.9 Million, or $0.26 Per Diluted Share, for the Third Quarter of 2026 RALEIGH, N.C. (October 27, 2026 ) – First Carolina Financial Services, Inc. (NYSE: FCBM) (“First Carolina,” the “Company,” “we,”

$FCBMMed

First Carolina Financial Services Reports Net Income of $5.1 Million, or $0.20 Per Diluted Share, for the Second Quarter of 2026

First Carolina Financial Services, Inc. (FCBM) filed an SEC Form 8-K — Results of Operations and Financial Condition. FOR IMMEDIATE RELEASE: First Carolina Financial Services Reports Net Income of $5.1 Million, or $0.20 Per Diluted Share, for the Second Quarter of 2026 RALEIGH, N.C. (July 30, 2026 ) – First Carolina Financial Services, Inc. (NYSE: FCBM) (“First Carolina,” the “Company,” “we,” “o

$LYCAMedAI 8/10

Venrock Healthcare Capital Partners III, L.P. (Koh Bong Y, Shah Nimish P) purchased $37.7M of LYCA (indirect holdings)

Venrock Healthcare Capital Partners III, L.P. purchased 2,045,440 indirectly-held shares of Lycia Therapeutics, Inc. (LYCA) at an average of $18.41 ($18.00–$26.97, $37.65M total) across 6 trades over 2026-10-23 to 2026-10-27. Filed jointly with VHCP Co-Investment Holdings III, LLC (10% owner), VHCP Management III, LLC (10% owner), Venrock Healthcare Capital Partners EG, L.P. (10% owner), VHCP Management EG, LLC (10% owner), Venrock Healthcare Capital Partners XP, L.P. (10% owner), VHCP Management XP, LLC (10% owner), Koh Bong Y (10% owner) and Shah Nimish P (10% owner).